TRIAL DATA
Real-world pembrolizumab data in dMMR mCRC shows 58% response rate, median PFS 37.9 monthsIn an Australian registry of 103 first-line pembrolizumab-treated patients (median age 75, 49% BRAF-mutant), median progression-free survival was 37.9 months and 12- and 24-month overall survival rates were 88% and 77%, though 17% had progressive disease as best response. (Clinical Colorectal Cancer)